3 Minute Read
The quality of status and sub-status data reported by SPs is an ongoing challenge that limits the actionability of data specialty brands have contracted to receive. Clearly, poor data...
4 Minute Read
Without visibility into each individual patient journey, your specialty brand cannot consistently intervene to help patients overcome barriers to therapy initiation and adherence. Today, the poor quality of specialty...
2 Minute Read
In this post IntegriChain Senior Vice President of Sales, Gary Palgon, shares the trending topic's from the 2018 CBI Life Sciences Trade & Channel conference held in Philadelphia, Pa...
4 Minute Read
An effective specialty data contracting strategy starts at the finish line and works backward. The decisions made in terms of data fields, sub-status granularity, reporting frequency, and contact language,...
4 Minute Read
The 340B program is subject to increasing scrutiny as pharmaceutical manufacturers search for solutions to identify and act on non-compliance such as diversion and duplicate discounts. This post is...
4 Minute Read
The American opioid crisis exposed gaps in the reporting systems designed to flag suspicious orders of pharmaceutical products classified as controlled substances. Pharmaceutical manufacturers are now facing increased scrutiny...
3 Minute Read
There are several ways specialty brands can improve patient initiation by implementing data-driven patient support strategies. Successful interventions to streamline patient initiation have the potential to speed Time to...
3 Minute Read
Rare diseases affect 30 million people in the United States, which roughly equates to 10% of the population. In 2017, 40% of the novel drugs approved by the FDA...